SecBot SecBot
SECBOTREPLAY Home › Report › DRTS

DRTS · Alpha Tau Medical announced that an abstract on Alpha DaRT in…

Alpha Tau Medical Ltd. · PRESS-RELEASE filed May 5, 2026 at 09:14 ET

At the news

BULLISHIMPACT 5/10

PRESS-RELEASE filed May 5, 2026 at 09:14 ET

Alpha Tau Medical announced that an abstract on Alpha DaRT in combination with pembrolizumab for elderly patients with head and neck cancer has been accepted for a podium presentation at the AHNS International Conference (July 18-22, 2026). This marks a strategic milestone for the company's combination therapy program, building on prior monotherapy data.

  • Abstract accepted for podium presentation at AHNS International Conference on Head and Neck Cancer (July 21, 2026)
  • Study evaluates Alpha DaRT + pembrolizumab in elderly patients with locally advanced/metastatic HNSCC
  • Complete top-line data to be presented; builds on prior monotherapy safety data
  • Elderly HNSCC patients have limited treatment options, representing a significant unmet need

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access